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(57) ABSTRACT 
Methods and compositions useful for neuronal protection in 
retinal cells in vitro and the protection of mammalian cells 
from reactive oxygen species in vivo are provided. Ultrafine 
nano-size cerium oxide particles, less than 10 nanometers in 
diameter, have been provided to decrease reactive oxygen 
species (ROS) in retina tissue that generates large amounts 
of ROS. These reactive oxygen species (ROS) are involved 
in light-induced retina degeneration and age-related macular 
degeneration (AMD). Cerium oxide nanoparticles have been 
used to promote the lifespan of retinal neurons and protect 
the neurons from apoptosis induced by hydrogen peroxide in 
vitro and in vivo. The neuronal protection in retinal cells is 
achieved by decreasing generation of intracellular reactive 
oxygen species (ROS). Thus, cerium oxide particles are used 
to promote the longevity of retinal neurons in vitro and 
mammalian cells in vivo. 
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INHIBITION OF REACTIVE OXYGEN 
SPECIES AND PROTECTION OF 
MAMMALIAN CELLS 
This is a Divisional of application Ser. No. 11/412,665 
filed Apr. 27, 2006 which claims the benefit of priority to 
U.S. Provisional Patent Application No. 60/676,043 filed 
Apr. 29, 2005 and claims benefit of U.S. Provisional Patent 
Application No. 60/716,630 filed Sep. 13, 2005. 
2 
metabolic insults from reactive oxygen species originating 
within or outside of the cells. These diseases include all 
forms of blindness whether hereditary, light-induced, or 
physical damage such as occurs in retinal detachment. In 
addition, damage due to ageing, stroke, cardiac infarction, 
burns, etc, which proceed through reactive oxygen species, 
can be addressed with the nanoceria particles of the present 
invention. 
The present invention promotes a longer lifespan for 
FIELD OF THE INVENTION 
10 retinal neurons. The greatest benefit of the nanoceria is its 
ability to get inside the cells and provide protection from 
reactive oxygen species (ROS); other body systems and 
tissues can also be protected from damage due to ROS. This invention relates to biological uses of nanoceria 
particles, and in particular to methods and compos1t10ns 
useful for neuronal protection in retinal cells in vitro and the 15 
protection of mammalian cells from reactive oxygen species 
SUMMARY OF THE INVENTION 
A primary objective of the present invention is to promote 
the lifespan of retinal neurons in culture. 
in vivo and is supported in part by funding from the National 
Science Foundation and National Institutes of Health under 
the Contract numbers: P20 RR! 7703, FY014427, FY13050, 
and FY12190. 
A secondary objective of the present invention is to 
20 protect retinal neurons from apoptosis induced by hydrogen 
peroxide (H20 2 ) in vitro. 
BACKGROUND AND PRIOR ART 
Cerium is a silvery metallic element, belonging to the 
lanthanide group. Cerium Oxide (Ce02 ) is used in precision 25 
polishing and lapping applications. Ultra fine nano-size 
cerium oxide, less than 10 nanometers, is more efficient for 
coating purposes. Recently, it was reported by B. Rzigalinski 
et al. that nanoparticles prolong the life of cortical neurons 
in culture 4 fold over the cells without treatment; decreased 30 
the intracellular Ca2+ concentration and prevented UV 
damage of cortical neurons. See B. Rzigalinski et al., 
"Cerium Oxide Nanoparticles Extend Cell Longevity and 
Act as Free Radical Scavengers" at website http://ww-
w.med.miami.edu/mnbws/Rzigalinskil 12.html. Based on its 35 
chemical characteristics, this effect is partially due to a 
decrease of reactive oxygen species (ROS). 
A third objective of the present invention is to protect 
retinal neurons from apoptosis induced by reactive oxygen 
species in vivo. 
A fourth objective of the present invention is to inhibit the 
rise in the intracellular concentration of reactive oxygen 
species (ROS). 
A fifth objective of the present invention is to provide 
method for inhibiting apoptosis induced by H20 2 of retinal 
neurons in vitro in a dose and time dependent manner. 
A sixth objective of the present invention is to provide 
method for inhibiting apoptosis induced by reactive oxygen 
species in retinal neurons in vivo in a dose and time 
dependent manner. 
A seventh objective of the present invention is to provide 
a method for preventing an increase in the intracellular 
reactive oxygen species (ROS) in a dose and time dependent 
manner. 
An eighth objective of the-present invention is to manu-
facture and modify cerium oxide (Ce02 ) nanoparticles for 
effective use in neuronal protection in retinal cells. 
Retina tissue generates a large amount of ROS which are 
involved in light-induced retina degeneration and age-re-
lated macular degeneration (AMD). The present invention 40 
tests the hypothesis that nanoparticles can promote the 
lifespan of retinal neurons in culture and protect them from 
apoptosis induced by hydrogen peroxide (H2 0 2 ) in vitro by 
decreasing the intracellular concentration of reactive oxygen 
species. 
A ninth objective of the present invention is to manufac-
ture and modify cerium oxide (Ce02 ) nanoparticles for 
effective use in mammalian cells in vivo to inhibit damage 
45 caused by reactive oxygen species (ROS). 
In 2004, T. H. Margrain et al. discuss the state of research 
in the treatment of age-related macular degeneration in 
Progress in Retinal and Eve Research, 2004, 23: 523-531, 
"Do Blue Light Filters Confer Protection Against Age-
Related Macular Degeneration?" The problem of apoptosis 
in the body is discussed in an article by P. Moongkarndi et 
al. in "Antiproliferation, Antioxidation and Induction of 
Apoptosis by Garcinia Mangostana (Mangosteen) on 
SKBR3 Human Breast Cancer Cell Line", Jl. ofEthnophar-
macology, 2004, 90: 161-166. 
Often persons suffering from light-induced retina degen-
eration and age-related macular degeneration (AMD) are 
without satisfactory remedies to prevent the eventual out-
come of blindness. There are some proteins available for 
neuronal protection of retinal cells, however, they are big 
molecules and over time their effect may fade away. 
It is desirable to find reliable solutions to prolong the 
lifespan of retinal neurons so that blindness is avoided for 
persons with retina degeneration and AMD. 
In addition to diseases of the eye, many human diseases 
are due to the death of cells in specific tissues or organs. The 
majority of those diseases are due to accumulation of 
A preferred composition for promoting longevity of reti-
nal neurons includes at least one of CeO.sub.nl wherein 
0<n1<2, and 0<n2<3 in the form of ultra-fine particles. The 
preferred ultra-fine particles have a diameter in a range 
50 between approximately 1 nanometer (nm) and approxi-
mately 10 nm and the preferred CeO.sub.nl is further 
defined as nl equals approximately 2. 
A preferred composition for inhibiting apoptosis induced 
by hydrogen peroxide oxidation of retinal neurons includes 
55 at least one ofCeO.sub.nl wherein 0<n1<2, and 0<n2<3 in 
the form of ultra-fine particles. The preferred ultra-fine 
particles have a diameter in a range between approximately 
1 nanometer (nm) and approximately 10 nm and the pre-
ferred CeO.sub.nl is further defined as nl equals approxi-
60 mately 2. 
A preferred composition for inhibiting apoptosis of retinal 
neurons in a dose and time dependent manner includes at 
least one of CeO.sub.nl wherein O<nl <2, and 0<n2<3 in the 
form of ultra-fine particles. The preferred ultra-fine particles 
65 have a diameter in a range between approximately 1 nanom-
eter (nm) and approximately 10 nm and the preferred 
CeO.sub.nl is further defined as nl equals approximately 2. 
US 7,347,987 B2 
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A more preferred composition that decreases the concen-
tration of intracellular reactive oxygen species (ROS) 
includes at least one of CeO.sub.nl wherein O<nl <2, and 
0<n2<3 in the form of ultra-fine particles. The more pre-
ferred composition is used in the treatment of diseases of the 
retina selected from the group consisting of light-induced 
retina degeneration and age-related macular degeneration, 
and is also used in vivo for the treatment of diseases in 
mammalian cells to inhibit damage caused by reactive 
oxygen species (ROS). 10 
The mammalian cells that can be treated by the compo-
sition of the present invention, include, but are not limited 
to, retinal neurons, brain cells, heart cells, skin cells, liver 
cells, kidney cells and peripheral nervous system cells. 
A preferred method for promoting longevity of retinal 15 
neurons includes preparing ultra-fine particles of at least one 
ofCeO.sub.nl wherein O<nl <2, and 0<n2<3 in a preselected 
concentration, and adding the preselected concentration of 
CeO.sub.nl wherein O<nl <2, and 0<n2<3 to primary retinal 
neurons. The preferred ultra-fine particles have a diameter in 20 
a range between approximately 1 nanometer (nm) and 
approximately 10 nm and the CeO.sub.nl is further defined 
as nl equals approximately 2. The preferred preselected 
concentrations of Ce02 are in a range between approxi-
mately 3 nanomolar (nM) and approximately fifty nanomo- 25 
lar (nM), more preferably in a range between approximately 
3 nanomolar (nM) and approximately twenty nanomolar 
(nM). 
It is also preferred that the preselected concentrations of 
Ce02 are added to primary retinal neurons in vitro and/or 30 
administered to mammalian cells in vivo to protect the 
mammalian body system from damage to any tissue due to 
reactive oxygen species (ROS). 
Further objects and advantages of the present invention 
will be apparent from the following detailed description of 35 
a presently preferred embodiment which is illustrated sche-
matically in the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
4 
FIG. 4G is a flow cytometry plot ofretinal neurons treated 
with 20 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
FIG. 4H is a flow cytometry plot ofretinal neurons treated 
with 20 nM cerium oxide. FIG. 5 shows relative viable 
retinal neurons with and without incubation of different 
concentrations of cerium oxide nanoparticles for time peri-
ods between approximately 12 hours and approximately 96 
hours. 
FIG. 6 shows the initial cerium oxide nanoparticle treat-
ments, hydrogen peroxide and DCFH-DA incubation, and 
time line of exposure. 
FIG. 7A is a graph of the intracellular level of reactive 
oxygen species (ROS) of retinal neurons after 30 minutes 
incubation with cerium oxide nanoparticles. 
FIG. 7B is a graph of the intracellular level of reactive 
oxygen species (ROS) of retinal neurons after 12 hours 
incubation with cerium oxide nanoparticles. 
FIG. 7C is a graph of the intracellular level of reactive 
oxygen species (ROS) of retinal neurons after 24 hours 
incubation with cerium oxide nanoparticles. 
FIG. 7D is a graph of the intracellular level of reactive 
oxygen species (ROS) of retinal neurons after 96 hours 
incubation with cerium oxide nanoparticles. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
FIG. 1 is a timeline of exposure of a primary retinal 
neuron culture to treatment with cerium oxide nanoparticles. 
The present invention has two embodiments describing in 
detail the in vitro and in vivo treatment of mammalian cells 
with ultra fine nano-size cerium oxide particles, less than 10 
nanometers in diameter, to protect the "body system" from 
40 damage to any tissue due to reactive oxygen species (ROS). 
FIG. 2 is a graph showing the percentage of apoptotic 
retinal neurons in culture with and without 5 nanomoles 
(nM) cerium oxide nanoparticle treatment at different time 45 
points. 
FIG. 3 shows the initial cerium oxide nanoparticle treat-
ments followed by hydrogen peroxide incubation, and time 
line of exposure. 
50 FIG. 4A is a flow cytometry plot of the control sample of 
primary retinal neurons with no cerium oxide nanoparticle 
treatments and no hydrogen peroxide incubation. 
Hydrogen peroxide (H2 0 2 ) is one of many reactive oxy-
gen species. In the present invention, H20 2 is added directly 
to cultures for the in vitro treatments. H2 0 2 is not added to 
the live tissue samples, since H2 0 2 is one of the ROS 
products of light damage. The discussion below confirms 
that nanoceria particles inhibit all forms of reactive oxygen 
species (ROS). 
For example, the nanoceria particles of the present inven-
tion can protect the brain against stroke and reperfusion 
injury, the heart cells from effects of cardiac infarction, the 
skin from UV rays and bum injuries. Neurodegeneration 
(e.g., Alzheimer's, Parkinson's, dementia, amyotrophic lat-
eral sclerosis) and potentially mental retardation (due to loss FIG. 4B is a flow cytometry plot of retinal neurons in the 
presence of 100 micromoles (µM) hydrogen peroxide. 
FIG. 4C is. a flow cytometry plot of retinal neurons 
treated with 1 nM cerium oxide in the presence of 100 
micromoles (µM) hydrogen peroxide. 
55 of brain cells) within the central and peripheral nervous 
systems can also be inhibited. This protection can extend to 
diseases which produce chronic problems such as cirrhosis 
of the liver or kidney or the multi-organ effects of aging 
itself. The nanoceria can become the universal treatment for FIG. 4D is a flow cytometry plot ofretinal neurons treated 
with 3 nM cerium oxide in the presence of 100 micromoles 60 
(µM) hydrogen peroxide. 
FIG. 4E is a flow cytometry plot ofretinal neurons treated 
with 5 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
FIG. 4F is a flow cytometry plot of retinal neurons treated 65 
with 10 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
all major and minor diseases and events which involve 
reactive oxygen species. 
The nanoceria (Ce02 nanoparticles) have the ability to 
destroy toxic products of metabolism known as reactive 
oxygen species (ROS). It has been shown in one embodi-
ment that the nanoceria particles prevent the ROS induced 
death of mammalian retinal neurons in culture (in vitro) and 
subsequently prolonged the life of the cells in culture and 
US 7,347,987 B2 
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protected the cells from ROS. In the second embodiment, 
the ability to provide mammalian cell protection in vivo is 
disclosed. 
The first embodiment of the present invention provides a 
method and composition for promoting the lifespan of 5 
retinal neurons and protecting the nerve cells in the eye from 
apoptosis induced by hydrogen peroxide (H2 0 2 ) in vitro by 
decreasing generation of intracellular reactive oxygen spe-
cies. The treatment of the eye with ultra fine nano-size 
cerium oxide is a significant advance in biological uses of 10 
cerium oxide. Persons afflicted with such conditions as, 
light-induced retina degeneration and age-related macular 
degeneration (AMD) have hope for brighter, clearer vision. 
The examples below provide further detail on the prepa-
ration and treatment of retinal nerve cells with Ce02 nano- 15 
particles. 
EXAMPLE 1 
6 
FIGS. 4A-4H are representative flow cytometry plots of 
retinal neurons with and without incubation with Ce02 
nanoparticles. Measurements were taken after 96 hours. The 
cytometry plot shows activity of approximately 10,000 cells 
in four quadrants, as described below. 
Cl represents the percentage of 10,000 cells showing 
Annexin V positive signals, which are interpreted to indicate 
the percentage of 10,000 cells undergoing apoptosis. 
C2 represents the percentage of 10,000 cells showing both 
Annexin V and PI positive signals, which is interpreted as 
the percentage of 10,000 cells which are in late apoptotic or 
necrotic stage. (Annexin V signals apoptotic stage; PI sig-
nals necrotic stage.) 
C3 represents the percentage of 10,000 cells showing 
neither Annexin V nor PI positive signals, which is inter-
preted as the percentage of 10,000 cells which are still 
viable. 
A primary retinal neuron culture is obtained from albino 
rat pups. Retinae of Sprague-Dawley albino rat pups (0-2-
day old) were dissected out and mechanically dissociated in 
C4 represents the percentage of 10,000 cells showing a PI 
20 positive signal, which is interpreted as the percentage of 
10,000 cells in a necrotic stage. 
25 ml of DMEM/F12 medium. After being filtered through 
230 µm and 140 µm sieves, the dissociated cells were 
centrifuged at 1200 rpm for 5 min. The cell pellets were 
re-suspended in the medium to 1xl05 cells/ml. 1 ml of the 
cell suspension was plated in each well pre-treated with 10 
µg/ml of poly-D-lysine. The cells were maintained in the 
medium until day 7, when different concentrations ofCe02 
nanoparticles were added to the cultures. The timeline for 
the addition of Ce02 nanoparticles is shown in FIG. 1. The 
treated neuronal cells were harvested on day 14, day 19, day 
Quadrants C2 and C4 show the percentage of 10,000 cells 
committed to die. In quadrant Cl the percentage of 10,000 
cells undergoing apoptosis are shown and some may be 
25 salvaged. It is important to observe the percentage of 10,000 
cells in quadrant C2 for the efficacy of the cerium oxide 
treatment of the present invention. 
Focusing on the viable cells, the control in FIG. 4Ahas no 
Ce02 nanoparticle treatment and 73.9% of the cell popula-
30 tion is viable after 96 hours. FIG. 4B is treated with 100 µM 
H2 0 2 , causing a deadly assault and leaving the lowest 
percentage (57 .7%) of viable cells. The addition of gradually 
increasing concentrations of cerium oxide with 100 µM 24 and day 29 after the beginning of treatment on day 7. The 
percentage of apoptotic retinal neurons in the culture with 
and without 5 nM Ce02 nanoparticle treatment is shown in 35 
FIG. 2 at the 12th day, 14th day, 19th day, 24th day and 29th 
day. Data are shown in M±S.D. Statistics were collected by 
Student t-test (n=3, *p<0.05, **p<0.01). FIG. 2 confirms 
that at every testing period the control with no Ce02 
nanoparticle treatment had a higher percentage of apoptotic 40 
retinal neurons in the culture, in contrast to the decreased 
percentage of apoptotic retinal neurons in the cells treated 
with 5 nM Ce02 nanoparticles. 
EXAMPLE 2 45 
The detection of apoptosis by flow cytometry is illustrated 
in FIGS. 3, 4A-4H and 5. After periods of incubation with 
Ce02 or H20 2 , the cells were washed with serum free 
medium 3 times, followed by treatment of 1 ml of 1 xtrypsin 50 
for 2 min. After centrifuging, the cell pellet was resuspended 
in 500 µl of lxPBS containing 5 µl of Annexin V-FITC and 
25 µl of Propidium Iodide (PI). The kit used for the analysis 
is commercially available from Beckman Coulter and is 
known as the "ANNEXIN V-FITC Kit." The mixture was 55 
incubated on ice for 10 minutes. The fluorescent emissions 
H2 0 2 , are shown in FIGS. 4C-4G. 
FIG. 4C is treated with 1 nM Ce02 nanoparticles and 100 
µM H2 0 2 and 60.6% of the cell population remains viable. 
FIG. 4D is treated with 3 nM Ce02 nanoparticles and 100 
µM H20 2 and 67.0% of the cell population is viable. FIG. 4E 
is treated with 5 nM Ce02 nanoparticles and 100 µM H20 2 , 
with 68.9% of the cell population remaining viable. FIG. 4F 
is treated with 10 nM Ce02 nanoparticles and 100 µM H20 2 
and 72.6% of the cell population is viable. FIG. 4G is treated 
with 20 nM Ce02 nanoparticles and 100 µM H2 0 2 and 
72.3% of the cell population remains viable. 
FIG. 4H is treated with 20 nM Ce02 nanoparticles without 
the addition of H2 0 2 and 73.4% of the cell population 
remains viable showing that the Ce02 nanoparticles alone 
have no negative effect on the cell population. 
The data in FIGS. 4A-4H can also be summarized from 
the analysis of cells undergoing apoptosis as shown in 
quadrant Cl. The control, FIG. 4A shows 16.2% of cells 
undergoing apoptosis under normal conditions, without any 
treatment, after 96 hours. FIG. 4B shows 26.1 % of cells 
undergoing apoptosis after the 100 µM H20 2 challenge. 
FIGS. 4C-4G show there are 28.3%, 21.9%, 22.2%, 18.5% 
and 15.8% of cells undergoing apoptosis with 1, 3, 5, 10 and 
20 nM Ce02 nanoparticle treatment, respectively. FIG. 4H 
shows 15.7% of cells undergoing apoptosis with 20 nM 
of FITC and PI were detected by flow cytometry (Beckman 
Coulter) with the excitation filters of 492 nanometers (nm) 
and 550 nm. The FITC fluorescent emissions signals the 
presence of cells undergoing apoptosis; whereas, the PI 
signals with an automatic red color fluorescence the binding 
to DNA fragments identifying cells in a necrotic stage. 
60 Ce02 nanoparticle treatment, which is a slight improvement 
over no treatment at all as shown by the control in FIG. 4A. 
FIG. 3 shows a treatment timeline with Ce02 incubation 
after the 7th day of treatment at the time intervals of 12 
hours, 24 hours, 72 hours and 96 hours with each treated 65 
sample subsequently exposed to 12 hours incubation time 
with H2 0 2 . 
Thus, cerium oxide nanoparticles inhibit apoptosis in 
retinal neurons in vitro in a dose and time dependent manner. 
FIG. 5 shows relative viable retinal neurons with and 
without incubation of different concentration of Ce02 nano-
particles for different time periods. The concentration of 
Ce0
2 
nanoparticles were 1 nM, 3 nM, 5 nM, 10 nM, 20 nM 
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each with 100 µM H20 2 ; one sample was treated with only 
100 µM H2 0 2 and another sample was treated with only 20 
nM Ce02 nanoparticles. The measurement of relative viable 
cells for each group was determined after 12 hours, 24 hours, 
48 hours, 72 hours and 96 hours. The effects showed dose 
and time dependency. 
5 nM cerium oxide nanoparticles started to decrease the 
apoptosis at 24 h of incubation. As incubation time 
increased, the protective effect from 5 nM nanoparticles was 
more significantly increased. Additionally, 100 nM and 20 10 
nM nanoparticles began to have effects late with 96 h of 
incubation. (Statistical analysis was done by ANOVA, and 
Duncan test for post hoc analysis. Data are presented in 
M±S.D. n~3, *p<0.05, **p<0.01). FIG. 5 shows that among 
the various treatment doses, 5nM Ce02 nanoparticle treat- 15 
ment gave the earliest response with moderate protective 
effect and 20 nM Ce02 nanoparticle treatment gave the 
highest protective effect with late response. 
8 
a dose and time dependent manner. It has also been deter-
mined that cerium oxide nanoparticles decrease generation 
of intracellular reactive oxygen species in a dose and time 
dependent manner. Thus, the present invention represents a 
significant advance in the treatment in degenerative diseases 
of the retina, such as, but not limited to light-induced retina 
degeneration and age-related macular degeneration (AMD). 
In the second embodiment of the present invention a rat 
"light damage" model for retinal degeneration was used as 
the test system. The data demonstrate that the nanoceria 
prevented the death of retinal neurons when given prior to 
the "light insult". The nanoceria particles protected the cells 
at the time of exposure as well as prevented the subsequent 
death seen days later in the untreated animals. The in vivo 
route of administration, including, direct injection into the 
eye, intravenous, intraperitoneal, intramuscular, oral or topi-
cally on the eye or skin may improve the result. Similarly, 
the time of administration of the nanoparticle, both before or 
EXAMPLE 3 
Intracelluar reactive oxygen species (ROS) production 
was measured in both Ce02 nanoparticle treated and control 
cells using 29, 79-dichlorofluorescein diacetate (DCFH-DA, 
Sigma). Briefly, the retinal neurons were exposed to Ce02 
nanoparticles with different concentrations and various incu-
bation times. After incubation, the cells were incubated with 
20 after an insult, is important. Thus, the nanoceria will also 
prevent the death of retinal cells due to glaucoma, diabetic 
retinopathy, inherited retinal degeneration (for example, 
Retinitis Pigmentosa), macular degeneration, retinal detach-
ment or any disease or event which proceeds through the 
25 production of ROS. These particles should preserve and 
prolong vision when administered in vivo. 
10 µM DCFH-DA (dissolved in dimethylsulfoxide 
(DMSO)) at 37° C. for 30 min. The cells then were incu-
bated with 1 mM H2 0 2 at 37° C. for 30 min after the excess 30 
DCFH-DA was washed with PBS. The cells were harvested 
as described above. The intensity of fluorescence was 
detected by flow cytometry with the excitation filter of 485 
nm. The ROS level was calculated as a ratio: ROS=mean 
intensity of treated cells divided by mean intensity of control 35 
cells. 
FIG. 6 is an experimental paradigm showing the begin-
ning of the Ce02 nanoparticle treatment on the 7th day and 
simultaneous incubation with H20 2 and DCFH-DA and a 
timeline of exposure at 30 minutes, 12 hours, 24 hours, and 40 
96 hours. FIGS. 7A-7D show how the Ce02 nanoparticles 
decreased the generation of ROS in a dose and time depen-
dent manner. The ROS generated in the groups of 5 nM, 10 
nM, and 20 nM nanoparticle incubation were statistically 
significantly less than the group without treatment at the 45 
earliest (12 h) of the tested points. 3 nM nanoparticle 
incubation had an effect at 24 h. However, 1 nM nanopar-
ticles did not show any significant decrease within the tested 
time point. Statistical analysis was done by ANOVA, and 
Duncan test for post hoc analysis. Data were shown in 50 
M±S.D. n=3, ** p<0.01; *p<0.05. 
The cerium oxide of the present invention includes those 
cerium compounds that have reacted with atmospheric oxy-
gen to have stable oxide layers identified as CeO.sub.nl, 
wherein 0 is less than 1 or equal to 2 (0<n1<2) and 55 
(0<n2<3). 
The cerium oxide particles of the present invention are 
characterized as ultra-fine and are preferably in a size range 
of from approximately 1 nanometer in diameter to approxi-
mately 10 nanometers in diameter; more preferably from 60 
approximately 1 nm to approximately 7 nm. A judicious 
selection of particle size is required by someone skilled in 
the art and is not a limitation of the present invention. 
The results of testing in the above examples document the 
ability of cerium oxide nanoparticles to promote the Ion- 65 
gevity of retinal neurons in vitro and inhibit apoptosis 
induced by hydrogen peroxide on retinal neurons in vitro in 
EXAMPLE 4 
Rats were injected intravitreally with 2 microliters (µ!)of 
nanoceria (concentrations from 0.1 to 1.0 micromolar) three 
days before they were exposed for six hours to a bright light 
(2700 LUX) in a light box. The animals were returned to 
normal lighting for 3.5 days, then killed, the eyes enucle-
ated, fixed, processed for paraffin embedding, sectioned, and 
either stained with H & E or processed for immunocy-
tochemistry. 
The number of photoreceptors remaining was determined 
with the H&E sections by using a microscope connected to 
a digital camera to record the images and then measuring the 
thickness of the outer nuclear layer every 240 microns from 
the optic nerve along both the superior and the inferior retina 
to the ora seratta. The data was then plotted as retina 
thickness versus the distance from the optic nerve head. The 
changes in other layers of retinal cells were recorded with 
images but not quantified. Cells actively undergoing apop-
tosis were also visualized using a commercially available 
"Apoptosis kit" and recording the microscopic images with 
a fluorescence microscope. 
The data demonstrate that the nanoceria at all concentra-
tions tested prevented the immediate death of retinal cells 
shortly after exposure to light as well as the ongoing death 
seen days later in the untreated animals. We therefore have 
demonstrated in vivo that these nanoceria particles can 
protect cells within the rat retina from light-induced cell 
death. 
Prior to the present invention, it was not known that 
nanoceria particles could be used in vivo for preventing 
blindness or death of retinal cells, or for preventing the death 
in vivo of any other cell type in any disease. The chemical 
properties of Ce02 nanoparticles enable the destruction of 
reactive oxygen species (ROS) produced by toxins and/or 
products of oxygen metabolism within cells. 
Thus, nanoceria can protect any cell type from ROS 
induced damages. Diseases which could possibly be pre-
vented, cured or ameliorated would include hereditary blind-
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ness, macular degeneration, glaucoma, diabetic retinopathy, 
retinal detachment, and other blinding diseases which 
involve ROS would be potentially solved. Similarly, in other 
cells within the central nervous system (CNS), neuronal 
death in strokes, degenerative diseases such as Alzheimer's 
Disease, Parkinson's, Huntington's Disease, and the death 
of peripheral nerves are preventable or at least the rate of cell 
death can be decreased and would result in prolonged 
function of the cells, tissues, organs, and individual. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
10 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 15 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. 
10 
We claim: 
1. A method for promoting longevity of retinal neurons 
comprising the steps of: preparing ultra-fine particles of at 
least one of Ce02 and Ce2 0 3 in concentration of approxi-
mately 3 nanomolar (nM) to approximately 50 nanomolar 
(nM) and administering said ultra-fine particles to the eye by 
direct injection or topically to protect the manimalian body 
system from damage to any tissue due to reactive oxygen 
species (ROS). 
2. The method of claim 1, wherein the ultra-fine particles 
have a diameter in a range between approximately 1 nanom-
eter (nm) and approximately 10 nm. 
3. The method of claim 1 comprising the step of preparing 
ultra-fine particles of Ce02 . 
4. The method of claim 3, wherein the concentration of 
Ce0
2 
is in a range between approximately 3 nanomolar (nM) 
and approximately fifty nanomolar (nM). 
* * * * * 
